Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDLakefront Biotherapeutics NV Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2026 | 1 | -$2.72 | -$0.03 | -$0.94 |
| Q2 2026 | 1 | -$2.37 | -$0.02 | -$0.82 |
| Q3 2026 | 1 | -$2.37 | -$0.02 | -$0.82 |
| Q4 2026 | 1 | -$3.42 | -$0.03 | -$1.19 |
| Q1 2027 | 1 | -$2.98 | -$0.03 | -$1.04 |
| Q2 2027 | 1 | -$3.05 | -$0.03 | -$1.06 |
| Q3 2027 | 1 | -$3.08 | -$0.03 | -$1.07 |
| Q4 2027 | 1 | -$3.12 | -$0.03 | -$1.08 |
| Q1 2028 | 1 | -$3.22 | -$0.03 | -$1.12 |
| Q2 2028 | 1 | -$3.29 | -$0.03 | -$1.14 |
| Q3 2028 | 1 | -$3.32 | -$0.03 | -$1.15 |
| Q4 2028 | 1 | -$3.39 | -$0.03 | -$1.18 |
Lakefront Biotherapeutics NV Earnings Date And Information
Lakefront Biotherapeutics NV last posted its earnings results on Wednesday, May 6th, 2026. The company reported $0.2473 earnings per share for the quarter, topping analysts' consensus estimates of $-0.94363 by $1.19093. The company had revenue of 6.48 M for the quarter and had revenue of 1.11 B for the year. Lakefront Biotherapeutics NV has generated $5 earnings per share over the last year ($4.87 diluted earnings per share) and currently has a price-to-earnings ratio of 3.42. Lakefront Biotherapeutics NV has not formally confirmed its next earnings publication date, but the company's estimated earnings date is N/A based on prior year's report dates.
Lakefront Biotherapeutics NV Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/31/2026 | Q1 2026 | N/A | $0.22 | N/A | $9.59 M | $6.48 M |
| 12/31/2025 | Q4 2025 | N/A | $11.87 | N/A | $82.87 M | $900.82 M |
| 09/30/2025 | Q3 2025 | N/A | -$3.07 | N/A | $76.10 M | $71.16 M |
| 06/30/2025 | Q2 2025 | N/A | -$1.60 | N/A | $80.08 M | $65.29 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Lakefront Biotherapeutics NV Earnings: FAQ's
In the previous quarter, Lakefront Biotherapeutics NV (:LKFT) reported $0.2473 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.94363 by $1.19093.
The conference call for Lakefront Biotherapeutics NV's latest earnings report can be listened to online.
The conference call transcript for Lakefront Biotherapeutics NV's latest earnings report can be read online.
Lakefront Biotherapeutics NV (:LKFT) has a recorded annual revenue of $1.11 B.
Lakefront Biotherapeutics NV (:LKFT) has a recorded net income of $320.88 M.Lakefront Biotherapeutics NV has generated $4.87 earnings per share over the last four quarters.
Lakefront Biotherapeutics NV (:LKFT) has a price-to-earnings ratio of 3.42 and price/earnings-to-growth ratio is -0.01.